Evidence map›Paper›PMID 18579551›Full record

ArticleThe European respiratory journal2008

Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD.

D M Mannino, D Thorn, A Swensen, F Holguin

Registry-linked trialOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in The European respiratory journal, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02889510 (Multicentre Randomized Double Blind, Crossover, Placebo Controlled Clinical Trial to Evaluate the Effect of Liraglutide on Lung Function in Patients With Type 2 Diabetes Mellitus), which is not on this map. Cited by 481 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
481citing papers in PubMed, 13 pooled it
25.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02889510 phase3completedstarted 2016, after this paper: background citation

Multicentre Randomized Double Blind, Crossover, Placebo Controlled Clinical Trial to Evaluate the Effect of Liraglutide on Lung Function in Patients With Type 2 Diabetes Mellitus (LIRALUNG Study)

Ran2016Enrolled76Registered outcomes8Posted comparisons0ConditionsType 2 DiabetesArmsliraglutide, Placebo
PMID 11282754PMID 14988297PMID 15526520PMID 18056886PMID 18285549PMID 19262746PMID 20217039PMID 20882512PMID 10960726other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

481 citing papers in PubMed, 13 syntheses or guidelines pooled it, 1,179 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. InhaledEuropean respiratory review : an official journal of the European Respiratory Society · 2024
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Review
  19. Observational
  20. Article

421 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

D M ManninoDept of Preventive Medicine and Environmental Health, University of Kentucky College of Public Health, Lexington, KY 40536, USA. dmannino@uky.edu
D Thorn
A Swensen
F Holguin
Tris Pharma (United States) · USUniversity of Kentucky · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is associated with important chronic comorbid diseases, including cardiovascular disease, diabetes and hypertension. The present study analysed data from 20,296 subjects aged > or =45 yrs at baseline in the Atherosclerosis Risk in Communities Study (ARIC) and the Cardiovascular Health Study (CHS). The sample was stratified based on baseline lung function data, according to modified Global Initiative for Obstructive Lung Disease (GOLD) criteria. Comorbid disease at baseline and death and hospitalisations over a 5-yr follow-up were then searched for. Lung function impairment was found to be associated with more comorbid disease. In logistic regression models adjusting for age, sex, race, smoking, body mass index and education, subjects with GOLD stage 3 or 4 COPD had a higher prevalence of diabetes (odds ratio (OR) 1.5, 95% confidence interval (CI) 1.1-1.9), hypertension (OR 1.6, 95% CI 1.3-1.9) and cardiovascular disease (OR 2.4, 95% CI 1.9-3.0). Comorbid disease was associated with a higher risk of hospitalisation and mortality that was worse in people with impaired lung function. Lung function impairment is associated with a higher risk of comorbid disease, which contributes to a higher risk of adverse outcomes of mortality and hospitalisations.

Indexed as

Cardiovascular DiseasesCohort StudiesDiabetes ComplicationsDiabetes MellitusFemaleHospitalizationHumansHypertensionMaleMiddle AgedPrevalencePrognosisPulmonary Disease, Chronic ObstructiveRiskTreatment Outcome

Identifiers

PMID18579551
OpenAlexW2169927995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.